MAZE CSBO Dandekar exercises 7,500 options, sells shares

Maze Therapeutics, Inc. executive Atul Dandekar reported an option exercise and planned share sales.

Rhea-AI Filing Summary

Maze Therapeutics, Inc. executive Atul Dandekar reported an option exercise and planned share sales. On January 29, 2026, he exercised a stock option for 7,500 shares of common stock at $10.42 per share, from a fully vested award. The same day, he sold 7,500 common shares in three trades: 1,200 shares at $43.1844, 3,500 shares at $44.0419, and 2,800 shares at $45.008, all under a pre-established Rule 10b5-1 trading plan. After these transactions, he reported owning 10,503 shares of common stock and 66,643 stock options, all held directly.

Insider Trade Summary

Exercise and Sale: 7,500 shares ($254K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Dandekar Atul

Role CSBO

Sold 7,500 shs ($332K)

Approx. gross sale proceeds $332K

Approx. exercise cost $78K

Approx. pre-tax spread $254K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	7,500	$0.00	$0.00
Exercise	Common Stock	7,500	$10.42	$78K
Sale	Common Stock	1,200	$43.1844	$52K
Sale	Common Stock	3,500	$44.0419	$154K
Sale	Common Stock	2,800	$45.008	$126K

Holdings After Transaction: Stock Option (Right to Buy) — 66,643 contracts (Direct); Common Stock — 10,503 shares (Direct)

Footnotes (5)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.49 to $43.46 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.51 to $44.49 per share, inclusive.
4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.54 to $45.53 per share, inclusive.
5. F5. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MAZE executive Atul Dandekar report on January 29, 2026?

Atul Dandekar reported exercising a stock option for 7,500 Maze Therapeutics common shares at $10.42 each, then selling 7,500 shares the same day in three trades at prices between $43.1844 and $45.008 per share under a Rule 10b5-1 trading plan.

How many Maze Therapeutics (MAZE) shares did Atul Dandekar sell and at what prices?

He sold a total of 7,500 Maze Therapeutics common shares: 1,200 shares at $43.1844, 3,500 shares at $44.0419, and 2,800 shares at $45.008. The filing notes these prices are weighted averages over multiple individual sale transactions in each price range.

What is the significance of the Rule 10b5-1 trading plan in the MAZE Form 4 filing?

The filing states the transactions were executed under a Rule 10b5-1 trading plan adopted on September 29, 2025. Such plans pre-schedule trades, helping insiders trade shares according to predetermined instructions, rather than on the basis of potential nonpublic information.

How many Maze Therapeutics (MAZE) shares and options does Atul Dandekar own after the reported trades?

After the January 29, 2026 transactions, he reported direct ownership of 10,503 shares of Maze Therapeutics common stock and 66,643 stock options. The option exercised for 7,500 shares was already fully vested under his award agreement with the company.

What details does the MAZE Form 4 provide about the exercised stock option?

The Form 4 shows a stock option to buy 7,500 Maze Therapeutics shares at an exercise price of $10.42. The option was fully vested, and the award became fully vested on March 17, 2025, according to the reporting person’s award agreement with the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dandekar Atul

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CSBO

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/29/2026		M(1)		7,500	A	$10.42	18,003	D
Common Stock	01/29/2026		S(1)		1,200	D	$43.1844(2)	16,803	D
Common Stock	01/29/2026		S(1)		3,500	D	$44.0419(3)	13,303	D
Common Stock	01/29/2026		S(1)		2,800	D	$45.008(4)	10,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.42	01/29/2026		M(1)			7,500	(5)	04/11/2031	Common Stock	7,500	$0	66,643	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.49 to $43.46 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.51 to $44.49 per share, inclusive.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.54 to $45.53 per share, inclusive.

5. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

	/s/ Courtney Phillips, as attorney-in-fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.